Fighting tubulin-targeting anticancer drug toxicity and resistance

The therapeutic potential of targeting ABC transporters to combat multi-drug resistance

(2017) Piyush Bugde et al.   EXPERT OPINION ON THERAPEUTIC TARGETS

The mechanics of microtubule networks in cell division

(2017) Scott Forth et al.   JOURNAL OF CELL BIOLOGY

Toward a Better Understanding of the Complexity of Cancer Drug Resistance

(2016) Michael M. Gottesman et al.   Annual Review of Pharmacology and Toxicology

PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer

(2016) Andreas D. Hartkopf et al.   Breast Care

Overview of the Formulations and Analogs in the Taxanes' Story

(2016) Farah Yassine et al.   CURRENT MEDICINAL CHEMISTRY

Cell cycle checkpoint in cancer: a therapeutically targetable double-edged sword

(2016) Roberta Visconti et al.   JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH

Use of poly ADP-ribose polymerase [PARP] inhibitors in cancer cells bearing DDR defects: the rationale for their inclusion in the clinic

(2016) Aniello Cerrato et al.   JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH

Castration-Resistant Prostate Cancer: AUA Guideline Amendment 2015

(2016) William T. Lowrance et al.   JOURNAL OF UROLOGY

Targeting WEE1 Kinase in Cancer

(2016) Christopher J. Matheson et al.   TRENDS IN PHARMACOLOGICAL SCIENCES

Systematic review of ixabepilone for treating metastatic breast cancer

(2016) Jing Li et al.   Breast Cancer

Molecular mechanisms underlying resistance to androgen deprivation therapy in prostate cancer

(2016) Kristine M. Wadosky et al.   Oncotarget

Identification of peptidic substrates for the human kinase Myt1 using peptide microarrays

(2015) Alexander Rohe et al.   BIOORGANIC & MEDICINAL CHEMISTRY

Antimitotic drugs in the treatment of cancer

(2015) Rustelle Janse van Vuuren et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

The Fcp1-Wee1-Cdk1 axis affects spindle assembly checkpoint robustness and sensitivity to antimicrotubule cancer drugs

(2015) R Visconti et al.   CELL DEATH AND DIFFERENTIATION

Antiandrogens Inhibit ABCB1 Efflux and ATPase Activity and Reverse Docetaxel Resistance in Advanced Prostate Cancer

(2015) Y. Zhu et al.   CLINICAL CANCER RESEARCH

Eribulin Mesylate: Mechanism of Action of a Unique Microtubule-Targeting Agent

(2015) N. F. Dybdal-Hargreaves et al.   CLINICAL CANCER RESEARCH

Drug Delivery Systems and Combination Therapy by Using Vinca Alkaloids

(2015) Chun-Ting Lee et al.   CURRENT TOPICS IN MEDICINAL CHEMISTRY

Corticosteroids in the Management of Prostate Cancer: A Critical Review

(2015) Chukwuma Ndibe et al.   CURRENT TREATMENT OPTIONS IN ONCOLOGY

Glucocorticoid receptor antagonism reverts docetaxel resistance in human prostate cancer

(2015) Jan Kroon et al.   ENDOCRINE-RELATED CANCER

Molecular Profiling and Targeted Therapy for Advanced Thoracic Malignancies: A Biomarker-Derived, Multiarm, Multihistology Phase II Basket Trial

(2015) Ariel Lopez-Chavez et al.   JOURNAL OF CLINICAL ONCOLOGY

Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer

(2015) Christopher J. Sweeney et al.   NEW ENGLAND JOURNAL OF MEDICINE

The role of taxanes in triple-negative breast cancer: literature review

(2015) Giorgio Mustacchi et al.   Drug Design Development and Therapy

Androgen receptor splice variants circumvent AR blockade by microtubule-targeting agents

(2015) Guanyi Zhang et al.   Oncotarget

Genome-wide CRISPR-Cas9 Screens Reveal Loss of Redundancy between PKMYT1 and WEE1 in Glioblastoma Stem-like Cells

(2015) Chad M. Toledo et al.   Cell Reports

Paclitaxel Through the Ages of Anticancer Therapy: Exploring Its Role in Chemoresistance and Radiation Therapy

(2015) Anna Barbuti et al.   Cancers

Nature as a remarkable chemist

(2014) Mansukh C. Wani et al.   ANTI-CANCER DRUGS

Androgen Receptor Splice Variants Determine Taxane Sensitivity in Prostate Cancer

(2014) Maria Thadani-Mulero et al.   CANCER RESEARCH

FDA Approval: Ado-Trastuzumab Emtansine for the Treatment of Patients with HER2-Positive Metastatic Breast Cancer

(2014) L. Amiri-Kordestani et al.   CLINICAL CANCER RESEARCH

Epothilones: From Discovery to Clinical Trials

(2014) Stefano Forli   CURRENT TOPICS IN MEDICINAL CHEMISTRY

Nanoways to overcome docetaxel resistance in prostate cancer

(2014) Aditya Ganju et al.   DRUG RESISTANCE UPDATES

Androgen Receptor as a Driver of Therapeutic Resistance in Advanced Prostate Cancer

(2014) Barbara Kahn et al.   International Journal of Biological Sciences

Docetaxel–carboxymethylcellulose nanoparticles display enhanced anti-tumor activity in murine models of castration-resistant prostate cancer

(2014) Bryan Hoang et al.   INTERNATIONAL JOURNAL OF PHARMACEUTICS

The glycoglycerolipid 1,2-dipalmitoyl-3-(N-palmitoyl-6′-amino-6′-deoxy-α-d-glucosyl)-sn-glycerol is no inhibitor of the human Myt1 kinase

(2014) Alexander Rohe et al.   JOURNAL OF ENZYME INHIBITION AND MEDICINAL CHEMISTRY

Synergistic blockade of mitotic exit by two chemical inhibitors of the APC/C

(2014) Katharine L. Sackton et al.   NATURE

Mitosis and apoptosis: how is the balance set?

(2013) Caroline H Topham et al.   CURRENT OPINION IN CELL BIOLOGY

A Randomised Phase 2 Study Combining LY2181308 Sodium (Survivin Antisense Oligonucleotide) with First-line Docetaxel/Prednisone in Patients with Castration-resistant Prostate Cancer

(2013) Paweł Wiechno et al.   EUROPEAN UROLOGY

Suppression of Acquired Docetaxel Resistance in Prostate Cancer through Depletion of Notch- and Hedgehog-Dependent Tumor-Initiating Cells

(2012) Josep Domingo-Domenech et al.   CANCER CELL

The end of mitosis from a phosphatase perspective

(2012) Roberta Visconti et al.   CELL CYCLE

Fcp1-dependent dephosphorylation is required for M-phase-promoting factor inactivation at mitosis exit

(2012) Roberta Visconti et al.   Nature Communications

Beyond taxanes: the next generation of microtubule-targeting agents

(2011) Javier Cortes et al.   BREAST CANCER RESEARCH AND TREATMENT

Taxane-Induced Blockade to Nuclear Accumulation of the Androgen Receptor Predicts Clinical Responses in Metastatic Prostate Cancer

(2011) M. S. Darshan et al.   CANCER RESEARCH

Improving Cancer Chemotherapy with Modulators of ABC Drug Transporters

(2011) S. Shukla et al.   CURRENT DRUG TARGETS

Management of metastatic castration-resistant prostate cancer after first-line docetaxel

(2011) J.A. Harrington et al.   EUROPEAN JOURNAL OF CANCER

Interplay between microtubule dynamics and intracellular organization

(2011) Hélène de Forges et al.   INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY

Mitotic Centromere-associated Kinesin (MCAK) Mediates Paclitaxel Resistance

(2011) Anutosh Ganguly et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Hypersensitivity reactions to anticancer agents: Data mining of the public version of the FDA adverse event reporting system, AERS

(2011) Kaori Kadoyama et al.   JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH

Characterisation and manipulation of docetaxel resistant prostate cancer cell lines

(2011) Amanda J O'Neill et al.   Molecular Cancer

Mitotic catastrophe: a mechanism for avoiding genomic instability

(2011) Ilio Vitale et al.   NATURE REVIEWS MOLECULAR CELL BIOLOGY

Pharmacologic Inhibition of the Anaphase-Promoting Complex Induces A Spindle Checkpoint-Dependent Mitotic Arrest in the Absence of Spindle Damage

(2010) Xing Zeng et al.   CANCER CELL

Triple-Negative Breast Cancer

(2010) Steven J. Isakoff   CANCER JOURNAL

Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial

(2010) Johann Sebastian de Bono et al.   LANCET

Evidence that Mitotic Exit Is a Better Cancer Therapeutic Target Than Spindle Assembly

(2009) Hsiao-Chun Huang et al.   CANCER CELL

Inhibition of the Androgen Receptor as a Novel Mechanism of Taxol Chemotherapy in Prostate Cancer

(2009) L. Gan et al.   CANCER RESEARCH

First total synthesis of 1,2-dipalmitoyl-3-( N -palmitoyl-6′-amino-6′-deoxy-α- d -glucosyl)- sn -glycerol—a glycoglycerolipid of a marine alga with a high inhibitor activity against human Myt1-kinase

(2009) Christiane Göllner et al.   CARBOHYDRATE RESEARCH

How do anti-mitotic drugs kill cancer cells?

(2009) K. E. Gascoigne et al.   JOURNAL OF CELL SCIENCE

Microtubule inhibitors: Differentiating tubulin-inhibiting agents based on mechanisms of action, clinical activity, and resistance

(2009) E. A. Perez   MOLECULAR CANCER THERAPEUTICS

Small-molecule inhibition of Wee1 kinase by MK-1775 selectively sensitizes p53-deficient tumor cells to DNA-damaging agents

(2009) H. Hirai et al.   MOLECULAR CANCER THERAPEUTICS

Docetaxel down-regulates the expression of androgen receptor and prostate-specific antigen but not prostate-specific membrane antigen in prostate cancer cell lines: Implications for PSA surrogacy

(2009) Kenji Kuroda et al.   PROSTATE